Partner David Rosen was quoted in an article published in FDA Week on April 18, 2014, titled “FDA Argument For 5-Year NCE Exclusivity Denial Unfounded, Gilead Says.” The article explains the appeal by Gilead Sciences, a manufacturer of one of three drug-drug combination products, asking the Federal Drug Administration (FDA) to reconsider its decision to prospectively change its new chemical entities policies for other combination drugs. Rosen was quoted saying, “One thing you can appreciate is FDA is very considered in its decision-making process at this time.”
People
Related News
29 November 2023
In the News
Daljit Doogal Discusses Foley’s Strategic Growth and Big Law Expansion Trends in Emerging Legal Markets
Foley & Lardner LLP Chairman and CEO Daljit Doogal is quoted in The American Lawyer article, “Big Fish, Small Ponds: How Big Law Is Slowly Infiltrating Emerging Markets,” offering insight on Foley’s continued national growth and Big Law expansion trends.
28 November 2023
In the News
Kyle Faget Discusses Coverage and Reimbursement for Telehealth Services
Foley & Lardner LLP partner Kyle Faget is interviewed by Healthcare IT Today in the article, “What’s a Problem, Technology, Opportunity, or Issue That Not Enough People are Talking About?”
22 November 2023
In the News
Naikang Tsao Assesses Copyright Act’s Fair Use Defense After Warhol Foundation v. Goldsmith
Foley & Lardner LLP partner Naikang Tsao authored the Westlaw Today article, “Still too subjective: the Copyright Act’s fair use defense after Andy Warhol Foundation v. Goldsmith.”